Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Tunisian lawyers call for strike over arrest of their colleague amid crackdown on dissentNorth Macedonia's new president reignites a spat with Greece at her inauguration ceremonyHundreds of prisoners set to be freed early to ease pressure on crowded jailsBizarre moment NYC crowd chants and cheers on man who ate 300 cheese balls in recordCatholic priest stuns worshippers by telling them Christ had an erection when he died on the crossNashville cop is fired after being busted over 'XEden Golan defies the protesters: Israel's hotly'Father of the 401(K)' reveals the biggest downside of his creationSwitzerland triumphs at the most political Eurovision ever: Nemo wins scandal'Father of the 401(K)' reveals the biggest downside of his creation
2.9617s , 6499.9609375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Global Gazette news portal